Precision Optics Corporation And 2 More Promising US Penny Stocks

In This Article:

As the U.S. stock market continues to reach record highs fueled by post-election optimism and favorable monetary policies, investors are on the lookout for promising opportunities beyond the well-known large-cap names. Penny stocks, often representing smaller or newer companies, remain a relevant investment area despite being considered an outdated term. By focusing on those with strong financial health and potential for growth, investors can uncover valuable opportunities in this niche market segment.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.7656

$5.56M

★★★★★★

RLX Technology (NYSE:RLX)

$1.63

$2.07B

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$170.72M

★★★★★★

AsiaFIN Holdings (OTCPK:ASFH)

$0.97

$79.11M

★★★★★★

Flexible Solutions International (NYSEAM:FSI)

$4.10

$51.05M

★★★★★★

PHX Minerals (NYSE:PHX)

$3.44

$128.99M

★★★★★☆

So-Young International (NasdaqGM:SY)

$1.25

$88.26M

★★★★☆☆

Permianville Royalty Trust (NYSE:PVL)

$1.55

$51.15M

★★★★★★

Puma Biotechnology (NasdaqGS:PBYI)

$2.88

$141.25M

★★★★★★

CBAK Energy Technology (NasdaqCM:CBAT)

$1.07

$96.23M

★★★★★☆

Click here to see the full list of 740 stocks from our US Penny Stocks screener.

We'll examine a selection from our screener results.

Precision Optics Corporation

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States, with a market cap of $31.75 million.

Operations: The company generates revenue of $19.10 million from its Surgical & Medical Equipment segment.

Market Cap: $31.75M

Precision Optics Corporation, with a market cap of US$31.75 million, faces challenges typical of penny stocks, including recent unprofitability and increased losses over the past year. Despite a decline in annual sales to US$19.1 million from US$21.04 million and a net loss increase to US$2.95 million, the company anticipates double-digit revenue growth for fiscal 2025 following resolution of production issues and strong product development sales. However, shareholders have faced dilution due to equity offerings while management's short tenure may raise concerns about leadership stability amidst these financial hurdles.

NasdaqCM:POCI Debt to Equity History and Analysis as at Nov 2024
NasdaqCM:POCI Debt to Equity History and Analysis as at Nov 2024

United States Antimony

Simply Wall St Financial Health Rating: ★★★★★★